Beijing Luzhu Biotechnology Co (HKSE:02480) Notes Receivable: HK$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02480 Beijing Luzhu Biotechnology Co Ltd HKSE:02480
24 GF Score
Price HK$13.00
! 3 Warning Signs
View Full Analysis

What is Beijing Luzhu Biotechnology Co Notes Receivable?

Beijing Luzhu Biotechnology Co HKSE:02480 24 Notes Receivable is HK$0.00 Mil as of Dec. 2025. GuruFocus rates HKSE:02480 with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Beijing Luzhu Biotechnology Co's Notes Receivable for the quarter that ended in Dec. 2025 was HK$0.00 Mil.

Beijing Luzhu Biotechnology Co Notes Receivable Related Terms

Beijing Luzhu Biotechnology Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for Beijing Luzhu Biotechnology Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Luzhu Biotechnology Co Notes Receivable Chart

Beijing Luzhu Biotechnology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
0.00 0.00 0.00 0.00 0.00

Beijing Luzhu Biotechnology Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:02480
24GF Score
Beijing Luzhu Biotechnology Co Ltd HKSE:02480
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Luzhu Biotechnology Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of HK$0.00 Mil mean?
Beijing Luzhu Biotechnology Co (HKSE:02480) has a Notes Receivable of HK$0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Beijing Luzhu Biotechnology Co and its competitors.
Is Beijing Luzhu Biotechnology Co's Notes Receivable too high?
Beijing Luzhu Biotechnology Co's current Notes Receivable is HK$0.00 Mil. Overall, Beijing Luzhu Biotechnology Co has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Luzhu Biotechnology Co's Notes Receivable compare to VRTX and REGN?
Beijing Luzhu Biotechnology Co's Notes Receivable of HK$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Beijing Luzhu Biotechnology Co and its competitors. Beijing Luzhu Biotechnology Co's current Notes Receivable is HK$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Luzhu Biotechnology Co stock overvalued right now?
Beijing Luzhu Biotechnology Co (HKSE:02480) has a current Notes Receivable of HK$0.00 Mil. The current Notes Receivable is HK$0.00 Mil. Beijing Luzhu Biotechnology Co's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Beijing Luzhu Biotechnology Co (HKSE:02480), the current Notes Receivable is HK$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beijing Luzhu Biotechnology Co Business Description

Address No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN
Beijing Luzhu Biotechnology Co., Ltd. is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group's product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
24GF Score

Get the complete analysis for HKSE:02480

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$13.00
Price